Cite
Semitala FC, Kadota JL, Musinguzi A, et al. Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial. PLoS Med. 2021;18(12):e1003875doi: 10.1371/journal.pmed.1003875.
Semitala, F. C., Kadota, J. L., Musinguzi, A., Nabunje, J., Welishe, F., Nakitende, A., Akello, L., Bishop, O., Patel, D., Sammann, A., Nahid, P., Belknap, R., Kamya, M. R., Handley, M. A., Phillips, P. P. J., Katahoire, A., Berger, C. A., Kiwanuka, N., Katamba, A., Dowdy, D. W., & Cattamanchi, A. (2021). Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial. PLoS medicine, 18(12), e1003875. https://doi.org/10.1371/journal.pmed.1003875
Semitala, Fred C, et al. "Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial." PLoS medicine vol. 18,12 (2021): e1003875. doi: https://doi.org/10.1371/journal.pmed.1003875
Semitala FC, Kadota JL, Musinguzi A, Nabunje J, Welishe F, Nakitende A, Akello L, Bishop O, Patel D, Sammann A, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PPJ, Katahoire A, Berger CA, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A. Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial. PLoS Med. 2021 Dec 16;18(12):e1003875. doi: 10.1371/journal.pmed.1003875. eCollection 2021 Dec. PMID: 34914696.
Copy
Download .nbib